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A TOUGH PILL TO SWALLOW: INCREASING
COMPLEXITY FOR DRUG DEVELOPERS IN
THE FEDERAL CIRCUIT
Jacob T. Michalakes *
I. INTRODUCTION
Society, as a whole, benefits from the increased public
health capabilities that result from a consistent, streamlined and
cost effective-drug development process. The FDA notes,
"speeding the availability of drugs that treat serious diseases are in•2
everyone's interest." It is essential that the regulatory, legislative
and judicial mechanisms in place work in sync so that drug
developers have a predictable journey when bringing a drug to
market. The need for a reliable system is increasingly important
' Jacob Michalakes is a 2020 DePaul College of Law J.D. Candidate. He
graduated from the University of Dayton with in Bachelor of Science' in
Biomedical Biology in 2016. While an ungraduated student in Dayton, Ohio,
Jacob was a member of a neurobiology research team that investigated the
biochemical mechanism of depression. After law school, Jacob hopes to pursue
a career in patent litigation, specifically in the pharmaceutical and
biotechnology spaces
U.S. Food & Drug Admin., Fast Track, Breakthrough Therapy, Accelerated
Approval, Priority Review (Feb. 23, 2018),
https://www.fda.gov/ForPatients/Approvals/Fast/ucm20041766.htm.
2id.
3 Id.
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with how the diversity of therapeutics is rapidly expanding. The
focus of this discussion will be on the recent development of
antibody patents and the challenges that drug developers are facing
in light of recent Federal Circuit holdings.5
Antibody treatments that involve the use of the patient's
own immune systems are inherently complicated but extremely
lucrative. 6 "These immune-system molecules form the basis of
drugs that rake in about US$100 billion per year.",7 A major player
in this market is Amgen Inc., who in early 2005 began developing
an antibody therapy to treat high cholesterol.8 The result of
Amgen's research and development was a drug named Repatha,
which was approved by the FDA in 2015. 9 Amgen obtained two
different patents involving Repatha that were later challenged by10
Sanofi, another major pharmaceutical developer. The result of
this litigation had profound effects on the drug development
process as a whole."
4 Charlotte Harrison, Patent Challenges to Antibody and Gene-Therapy Firms on the
Rise, NATURE BIOTECHNOLOGY, (May 9, 2018),
https://www.nature.com/articles/nbt0518-382.
5 Biosimilar Development, Patent Eligibility of Biologic & Biosimilar Patents
A Primer (Jan. 2, 2018),
https://www.biosimilardevelopment.com/doc/patent-eligibility-of-biologic-biosi
milar-patents-a-primer-000 1.
6 1d.
7 Hedi Ledford, Rush to Protect Lucrative Antibody Patents Kicks Into Gear
(May 25, 2018), https://www.nature.com/articles/d41586-018-05273-z.
8 Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017).
9 1d. at 1371.
'old.at 1372.
1 Dani Kass, Fed Circ. Created Disclosure 'Anarchy,' Amgen Tells Justices. (Aug.
7,2018),
https://www-law360-com.ezproxy.depaul.edu/articles/1070997/fed-circ-created-disclosur
e-anarchy-amgen-tells-justices.
110
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In Amgen Inc., et al., v. Sanofi, et al., the Federal Circuit
held Amgen's patents to a different standard then that required by
the Patent Act in regard to the written description and enablement
requirements.12 The court made an already complicated landscape
even more challenging and unpredictable.l-
Part II of this note, will discuss the Court's deviation from
the Patent Act and the implications it has on Amgen's prospects of
clearing their patents Part III, will discuss the larger ramifications
this holding has on the drug development process. It will also
analyze the complexity of the new standard the Federal Circuit is
creating. Finally, Part V will conclude the overall discussion. 17
II. BACKGROUND
Patent law in the United States traces its roots back to the18
constitution. Article 1, Section 8, Clause 8 states: [Congress shall
have power] "To promote the progress of science and useful arts,
by securing for limited times to authors and inventors the
exclusive right to their respective writings and discovenies."' 9 This
clause did not create an automatic right for inventors to receive
1 Supra note 4.
13 Supra note 7.
14 See infra note 18 - 35 and accompanying text.
15 See infra notes 36 - 92 and accompanying text.
6 1d.
17 See infra notes 93 - 105 and accompanying text.
8 U.S. Const. art. I, §8, cl. 8.
'
91d.
2018]
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patents, but rather, enabled Congress to create a patent system
through subsequent legislation.
Wide sweeping legislative action in the realm of patent law
occurred in 1952 with the passing of the Patent Act of 1952.2 The
act, codified at Title 35 of the United States Code, modernized and
simplified patent law in the United States. The most recent
amendments to the Patent Act occurred in 2011 with the passing of23
the Leahy-Smith America Invents Act (AIA).
A. Written Description
Section 112 of the Patent Act states that "[t]he specification
shall contain a written description of the invention... in such full,
clear, concise, and exact terms as to enable any person skilled in
the art to which it pertains ... to make and use the 
same .... 24
The purpose of this requirement is for the inventor to prove that
they, "had possession of the claimed subject matter as of the filing" 25 ""a
date. Proving possession requires, "a precise definition of the
invention."
Proving possession becomes more difficult when an
inventor attempts to claim a generic group of inventions instead of
20 Ladas & Perry, LLP, A Brief History of the Patent Law of the United States,
(May 7, 2014),
https://adas.com/education-center/a-brief-history-of-the-patent-law-f-the-unite
d-states-2/.
21 ]d.
22 supra.
23 supra.
24 35 U.S.C. § 112(a).
2 5AriadPharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed.Cir. 2010) (en
banc).
26 ]d.
112
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S27
a specific single entity. For the inventor to give a precise
definition of the generic group, the Ariad court requires: "a
patentee must disclose a representative number of species falling
within the scope of the genus or structural features common to the
members of the genus so that one of skill in the art can 'visualize
or recognize' the members of the genus. 28
Proving possession is unic9iely challenging when the
invention is a molecule or antibody. The court in Enzo, created a
mechanism for inventors to prove possession of antibodies. 30 The
Federal Circuit held "as long as an applicant has disclosed a 'fully
characterized antigen,' either by its structure, formula, chemical
name, or physical properties, or by depositing the protein in a
public depository, the applicant can then claim an antibody by its
binding affinity to that described antigen.",
3
'
B. Enablement
The Enablement requirement of a patent application has the
32same statutory roots as the written description requirement.
Section 112 of the Patent Act reads "[t]he specification shall
contain a written description of the invention . . . in such full,
clear, concise, and exact terms as to enable any person skilled in
the art to which it pertains . . . to make and use the same."
27 See generally Brief for Bristol-Meyer Squib Company as Amici Curiae
Supporting Petitioner, Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed.
Cir. 2017) (No. 17-1480) [hereinafter Brief for Bristol-Meyer Squib].2 8Ariad Pharm., Inc. at 1351.
29 Brief for Bristol-Meyer Squib at 7.
3 0 Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 965 (Fed.Cir. 2002).
3' Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed.Cir. 2004).
32 35 U.S.C. § 112(a).
33 id.
2018]
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Determination of whether the written description is enabling turns
on the question, "is the experimentation needed to practice the
invention undue or unreasonable?" Even though the words "undue
experimentation" aren't found in the Patent Act itself, this has
become the standard adopted by the Federal Circuit.34
Il. ANALYSIS
A. Amgen Inc., et al. v. Sanofi, et el
The district court held that Amgen's patents, U.S. Patent
No. 8,829,165 ('165 Patent) and No. 8,859,741 ('741 patent), were
valid and granted a permanent injunction enjoining the sale of
31
Sanofi's product. Sanofi appealed that judgment claiming the
district court improperly excluded post-priority date evidence
regarding written description and enablement that proffered to
show that written description and enablement were inadequate.36
The Federal Circuit held that the district court erred by excluding
Sanofi's evidence regarding written description and enablement
and reversed and remanded the case.
Sanofi sought to introduce evidence to show that Amgen's
patents did not disclose a representative number of species and• 37
therefore the written deception not proving possession. However,
Amgen claims the "Possession Standard," which the Federal
Circuit used to gage the sufficiency of the written description, has
no statutory basis and defies court precedent.
3 4 1n re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
3 5 Amgen Inc., 872 F.3d at 1371.
36 1d.
37 Id. at 1374.
31 Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017), petition
for cert. filed, (U.S. Jul. 23, 2017) (No. 2017-1480).
6
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B. Written Description of the 1 65 Patent
At the heart of the written description requirement is the
"quid pro quo" of patent law.39 The patent applicant, in exchange
for describing and disclosing their invention to the public (quid),
receives a right to exclude others (quo) from using their invention.
4oThe exchange of sufficient description of invention for the right
to exclude is the ultimate purpose of the patent system and more
specifically, the goal of § 112(a). 4 The following theme has been
woven through case law for decades, "the object of the statute is to
require the patentee to describe his invention so that others may
construct and use it after the expiration of the patent.",42 Amgen
has upheld its side of the bargain in the written description of its
'165 patent and is consistent with the object and purpose of
§112(a). 4 ' However, the Federal Circuit has ruled Amgen's '.165
patent invalid because it does not comply with the extra-statutory
standard the court has created. 44
Amgen's '165 patent disclosed the active ingredients in
their drug Repatha TM .4 Claim of patent '165 states:
An isolated monoclonal antibody, wherein, when bound to
PCSK9, the monoclonal antibody binds to at least
3 Universal Oil Prods. Co. v. Globe Oil & Ref, Co., 322 U.S. 471, 484 (1944).
40 Id.
4' Brief for Bristol-Meyer Squib, p. 7, Amgen Inc., et al., v. Sanofi, et al., 872
F.3d 1367 (Fed. Cir. 2017).
42 Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47, 57 (1938).
43 Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017), petition
for cert. filed, (U.S. Jul. 23, 2017) (No. 2017-1480) at 3.
44Id. at5.
4' Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367, 1372 (Fed. Cir. 2017).
2018]
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one of the following residues: S153, 1154, P155,
R194, D238, A239, 1369, S372, D374, C375, T377,
C378, F379, V380, or S381 of SEQ ID NO:3, and
wherein the monoclonal antibody blocks binding of
PCSK9 to LDL [-]R."
Under the standard created by the Federal Circuit, in order for
Amgen to adequately prove they have actually invented their
claimed invention, Amgen must show in its disclosure that it had
"possession" of the subject matter that they are claiming at the
47
time they filed the patent application. The crux of the matter is
that showing possession becomes extremely difficult when the48
subject matter of the patent is a drug or biologic. Showing
possession of an antibody that ligates a certain residue on a protein
is immensely more complicated to show possession as compared
to possessing a mechanical device that can be physically 
held.49
The Federal Circuit created another rule that attempts to
address this issue.5° In doing so, the court only made the uphill
battle for drug developers even steeper.5" When a patentee is
claiming a general group of molecules that achieve the same goal,
they are claiming a genus patent.5 2 A patent claiming a genus must
disclose: "a representative number of species falling within the
scope of the genus or structural features common to the members
46 U.S. Patent No. 8,829,165 (Simon M. Jackson).
4' Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1350 (Fed. Cir. 2010)
(en banc).
4' Brief for Bristol-Meyer Squib, p. 15, Amgen Inc., et al., v. Sanofi, et al., 872
F.3d 1367 (Fed. Cir. 2017).
41 Supra note 31.
5o Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017), petition
for cert. filed, (U.S. Jul. 23, 2017) (No. 2017-1480) at 11.
51 Id.
52Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367, 1374 (Fed. Cir. 2017).
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of the genus so that one of skill in the art can 'visualize or
recognize' the members of the genus."53
In Amgen's '165 patent, they are claiming a genus patent.
Here, Amgen is claiming "An isolated monoclonal antibody,
wherein, when bound to PCSK9, the monoclonal antibody binds to
at least one of the following residues," followed by a list of
potential residues on the protein, which could potentially serve as
55an antigen for the antibody to ligate to. The genus is any antibody
that binds to one of listed residues and preforms the function of
destroying LDL-receptor cells.16 Additionally, Amgen provided in
the specification of the '165 patent: "the three-dimensional
structures, obtained via x-ray crystallography, of two of the
antibodies known to bind the residues recited." This information
was put forward to satisfy the extra-statutory rule of requiring a
patent to disclose "a representative number of species falling
within the scope of the genus or structural features common to the
members of the genus."
The information that Amgen submitted to satisfy the
"possession" standard to the Federal Circuit goes above and
beyond what other patent applicants must disclose in order to
receive patent protection. Referring back to the "quid pro quo"
argument, the Federal Circuit is requiring Amgen to give "quid
" Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010)
(en banc).
54Amgen at 1372.
55 Id.
56 id.
57 Id.
58 Amgen 872 F.3d 1372 (quoting Ariad Pharm., Inc. v. Eli Lilly & Co., 958
F.3d 1336, 1351 (Fed. Cir. 2010)).
59Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367, 1373 (Fed. Cir. 2017).
2018]
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60
plus" in order to receive the quo of patent protection. This is
both in contravention of the plain letter and spirit of the patent
code in § 112(a).6 ' To make matters even more complicated, the
Court in Amgen allowed Sanofi to enter post-priority-date
evidence to show that Amgen's patent does not disclose a
representative number of species of a claimed genius and therefore
does not have possession of the invention for written description
62
sake. The Federal Circuit has been silent as to whether this type
of evidence can be offered up until the decision 
in Amgen.
Unless, the Supreme Court grants certiorari and reverses this
decision, drug developers not only have to prove more to receive a
patent, but also additional evidence can be used against them to
prove they are not entitled to patent protection. This further adds
to the complexity and unpredictability that results from Amgen's
holding.65
C. Enablement of the '165 Patent
Similar to the written description requirement, the
enablement requirement is a mechanism to ensure the inventor
knows the extent of what they have invented before they receive a
60 Universal Oil Prods. Co. v. Globe Oil & Ref Co., 322 U.S. 471, 484 (1944)
(explaining the "quid pro quo" of patent law, here the concept is taken beyond
its intended scope).
6! Brief for Bristol-Meyer Squib at 7.
62Amgen 872 F.3d at 1370.
63 Amgen at 1374 (Citing In re Hogan 559 F.2d 595 (CCPA 1977)).
64 Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017), petition
for cert. filed, (U.S. Jul. 23, 2017) (No. 2017-1480 ) at 2.
65 Amgen Inc., Amgen Manufacturing Limited, Amgen USA, Inc., v. Sanofi,
Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S., LLC,
2017 WL 6760911 *6 (C.A.Fed.).
10
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right to exclude. The specification of the patent is sufficiently
enabling, according to § I 12(a) of the patent statute, if the written
description is clear and concise enough to enable a terson
ordinarily skilled in the art to actually use the invention. The
enablement requirement also serves the purpose of being the
middleman in the "quid pro quo" of patent law.68 Whatever the
patent applicant is disclosing is only of value to the public if it
clearly and concisely enables a person ordinarily skilled in the art
69to use the invention without undue experimentation.
The Federal Circuit bifurcated its analysis of the
sufficiency of Amgen's '165 patent specification. It frst
analyzed whether evidence submitted after the patent application
was filed was allowed to be submitted to prove that the written
description was insufficient. 7 The Court went on to analyze
whether post-priority date evidence could be entered to show that
undue experimentation was needed to determine how to use
Amgen's 2patent, therefore causing the specification to not be
enabling.
The Federal Circuit separating the analysis into two
different inquiries goes directly against the purpose of the patent
act. "The Act sets forth a single standard for the written
description: It must be "in such full, clear, concise, and exact terms
as to enable any person skilled in the art... to make and use" the
66 id
6735 U.S.C. § 112(a) (2012).
68 Amgen Inc., Amgen Manufacturing Limited, Amgen USA, Inc., v. Sanof,
Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S., LLC,
2017 WL 6760911 *7 (C.A.Fed.).
"9In re Wands at 858 F.2d 731.
70 Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367, 1375 (Fed. Cir. 2017).
71 id.
72 Id.
2018]
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invention. 73 Allowing Sanofi to submit evidence to prove lack of
enablement separate from allowing evidence to show lack of
possession, adds to the lack of consistency and another layer of
complexity to an already complicated process.
D. Impact on the Pharmaceutical Company
In both Amgen's petition for Writ of Certiorari and76
Bristol-Meyers Amicus Curiae Brief , the extent of the adverse
effects of the holding in Amgen cannot be understated. The single
most dispositive variable that determines whether a drug will be
developed and eventually made available to patients is the cost to77
bring the drug to market. Drug developers spend gargantuan
amounts of money researching and developing cutting-edge
therapies for patients with medical needs that have no remedy yet.
78 Return on investment is primarily secured through drug
developers receiving patent protection on their innovations.
A unique issue presents itself when the patent being sought80
is a genus patent, similar to the Amgen '165 patent. Because of
the relative ease to develop a drug similar to one already patented
without infringing it, drug developers need to be able to claim
7' Amgen Inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017), petition
for cert. filed, (U.S. Jul. 23, 2017) (No. 2017-1480 ) at 11.
741d. at 12.
75 Id. at 4.
76 Amgen Inc., Amgen Manufacturing Limited, Amgen USA, Inc., v. Sanof,
Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S., LLC,
2017 WL 6760911 *7 (C.A.Fed.).
77 id.
78Id. at *1.
79 Id. at *5.
80 Amgen inc., et al., v. Sanofi, et al., 872 F.3d 1367 (Fed. Cir. 2017),petition
for cert. filed, (U.S. Jul. 23, 2017) (No. 2017-1480 ) at 20.
120
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genus patents and have confidence that the application process will
be similar to any other patent application. 8' The only way to ensure
that drug developers are rewarded for their expenditure of
resources and the risk taken to develop the breakthrough
discoveries is through robust patent protection on an entire group
(or "genus") of antibodies that bind to the desired target. Without
the ability to patent the entire genus, the drug developer would be
spending time and money developing a drug that could potentially
be worthless because a competitor circumvented their patent.
This goes to show that the Federal Circuit ignored market realities
when they decided to create their own standard to review written
• . 84
description and enablement of patent applications.
The secondary impact that results from drug developers'
lack of certainty about obtaining patent protection for their "
breakthroughs is felt by patients and society as a whole. 85 Patients'
and society's overall health and wellness is dependent on
pharmaceutical companies investing in research and eventually6
developing drugs to meet the unmet medical needs of society.
Because of the extensive knowledge and capital necessary to
develop new therapies, drug companies are best situated to do so.,
87 Society, although maybe not most efficiently, places this
enormous responsibility in the hands of pharmaceutical88
companies. It is farsighted and prudent for courts to interpret
81 Id
82 Id. at 6.
83See generally Amgen inc., Amgen Manufacturing Limited, Amgen USA, Inc., v.
Sanof, Aventisub LLC, Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S.,
LLC, 2017 WL 6760911 *5 (C.A.Fed.)..
84 id.
851Id. at *1.
86 Id.
87 Id. at *2.
88Id. at*5.
2018]
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laws in a way that reduces the complexity and cost of drug
development. This will encourage drug development and result90
in an overall net benefit for society. The holding in Amgen is
diametrically opposed to this thought process and, for that reason,
stifles drug research and development.
IV. CONCLUSION
The Federal Circuit's holding in Amgen incorrectly
bifurcated the written description requirement of 35 USC § 112(a)
into two separate requirements each held to a different standard.
The Federal Circuit now requires the specification to be
sufficiently described as to "enable a person of skill to make and
use the invention." 9 Additionally, the written description must
show "possession" of the invention. 94The Federal Circuit cleaved
the unitary standard of § 112(a) into two separate requirements -
"enablement" and "written description." 95 This departs from a
89See generally Amgen Inc., Amgen Manufacturing Limited, Amgen USA, Inc.,
Plaintiffs-Appellees, v. Sanof, Aventisub LLC, Regeneron Pharmaceuticals Inc.,
Sanofi-Aventis U.S., LLC, Defendants-Appellants., 2017 WL 6760911, at *5
(C.A.Fed.).
90 Id.
9' See generally Amgen Inc. v. Sanofi, , 872 F. 3d 1367 (Fed. Cir. 2017), petition
for cert.filed, (U.S. Jul. 23, 2017) (No. 2017-1480).
92 Id.
93 Id. at *4.
94 Id. at *7.
9' AMGEN INC., Amgen Manufacturing Limited, Amgen USA, Inc.,
Plaintiffs-Appellees, v. SANOFI, AVENTISUB LLC, Regeneron
Pharmaceuticals Inc., Sanofi-Aventis U.S., LLC, Defendants-Appellants., 2017
WL 6760911, at *4 (C.A.Fed.).
122
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foundation of precedent and conflates the purpose and plain
meaning of § 1 12(a). 96
Bristol-Myers Squibb states: The Federal Circuit's
approach makes it exceedingly difficult to obtain robust patent
protection for biopharmaceutical innovations and consequently
impedes progress in this field. Additionally, Bristol-Meyers
reminds the court that pharmaceutical companies such as Amgen,
spend enormous amounts of money to research and develop new
therapies for patients with unmet medical needs. 9' If growth in the
field of pharmaceutical development is impeded or made more
complex because of arbitrary application of laws, then society as a
whole will suffer because therapies will be unavailable to patients.
99 Complicating the process for drug developers to bring their
inventions to market has larger implications than any other
segment of the market because these inventions alleviate human
suffering and cure diseases the public suffers from. 100
On July 2 3rd, 2018, Amgen, Inc. filed its Petition for a Writ
of Certiorari to the Supreme Court of the United States. 101 Amgen,
is presenting this question: should the standard for determining the
adequacy of the "written description of the invention" be as the,
statute says or should court-created standards control instead? 102
Optimistically, the Supreme Court will grant Amgen's petition of
Certiorari and return written description jurisprudence back within
96Id. at *1.
97 Id. at 3.
98 1d. at 1.
9'Id. at2.
"Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review,
U.S. FOOD & DRUG ADMIN., (Feb. 23, 2018),
https://www.fda.gov/ForPatients/Approvals/Fast/ucm20041766.htm.
" Amgen Inc. v. Sanofi, 872 F.3d 1367 (Fed. Cir. 2017),petition for cert. filed,
(U.S. Jul. 23, 2017) (No. 2017-1480) at 1.
' Id. at 7.
2018]
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10l3
the confines of 35 U.S.C. § 112 where it belongs. This can be
done by abolishing the conflated standard the Federal Circuit is
constructing on their own before its adverse effects are felt by
society as a whole. 104
103 Id. at 5.
1
.See generally Amgen Inc., Amgen Manufacturing Limited, Amgen USA, Inc.,
Plaintiffs-Appellees, v. Sanofi, Aventisub LLC, Regeneron Pharmaceuticals Inc.,
Sanofi-Aventis U.S., LLC, Defendants-Appellants., 2017 WL 6760911, at *5
(C.A.Fed.).
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